Title |
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia
|
---|---|
Published in |
BMC Psychiatry, October 2013
|
DOI | 10.1186/1471-244x-13-243 |
Pubmed ID | |
Authors |
Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata |
Abstract |
It is desirable to establish evidence for the selection of antipsychotics from the viewpoint of recovery of social activity in individual patient with schizophrenia receiving medication. From this perspective, awareness of the importance of studies about drug effectiveness on treatment discontinuation rate, remission rate, and improvement in QOL has grown recently. In Western countries, numerous reports are available in effectiveness studies, which are related to olanzapine and risperidone primarily, whereas evidence for other second-generation antipsychotics (SGAs) is poor. In Japan, no effectiveness study has been reported: thus, it is desirable to collect data that will serve as evidence for selection of the 3 SGAs approved after olanzapine. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Unknown | 86 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 14% |
Researcher | 11 | 13% |
Student > Bachelor | 11 | 13% |
Other | 8 | 9% |
Student > Ph. D. Student | 7 | 8% |
Other | 18 | 21% |
Unknown | 20 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 25% |
Nursing and Health Professions | 7 | 8% |
Psychology | 7 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
Social Sciences | 5 | 6% |
Other | 15 | 17% |
Unknown | 25 | 29% |